Why Regulatory Liabilities Matter During Healthcare Acquisitions

 Healthcare acquisitions involve more than assessing revenue, assets and growth prospects. A buyer also needs to understand the regulatory responsibilities attached to the target business.

Hospitals, pharmaceutical companies, diagnostic centres, medical device businesses and digital health companies operate within detailed regulatory frameworks. Their licences, approvals, professional obligations, product standards and data practices can all affect the value and continuity of the business.

A regulatory issue may not always appear as a conventional financial liability. However, it can create significant costs after an acquisition. A missing approval, unresolved investigation or non compliant product can affect operations, reputation and future investment. This is why regulatory liabilities should form an important part of healthcare M&A due diligence.

What Are Regulatory Liabilities?

Regulatory liabilities are obligations, risks or potential consequences arising from a company's failure to comply with applicable laws and regulatory requirements. They can include unpaid penalties, regulatory proceedings, licence issues, product compliance concerns and unresolved notices. Some liabilities are already known. Others may only become apparent during a detailed review.

A buyer therefore needs to examine both existing regulatory liabilities and potential exposure arising from past conduct. The analysis can be particularly important in healthcare because regulatory compliance often affects whether a business can legally continue its core operations.

Why Regulatory Liabilities Matter More in Healthcare

Healthcare businesses operate in areas directly connected with public health and safety. A hospital depends on licences and standards relating to its facilities and clinical operations. A pharmaceutical company must comply with requirements governing medicines. A medical device manufacturer may need to meet product specific standards.

These obligations can differ considerably from those applicable to an ordinary commercial business. A regulatory problem can therefore affect more than the company's finances. It can interfere with the ability to provide products or services.

Licences Can Affect Business Continuity

Licences and registrations are often fundamental assets in healthcare transactions. A buyer should determine which licences the target holds, who holds them and whether they remain valid. The review should also consider renewal dates, conditions attached to approvals and any history of suspension or regulatory action.

A change in ownership may also affect certain regulatory permissions depending on the relevant legislation. If an essential approval cannot be transferred or requires prior consent, the transaction structure may need to account for this issue.

Regulatory Notices Should Not Be Overlooked

A target may have received regulatory notices without the matter having developed into formal litigation. Such correspondence can still be important. A notice may indicate an inspection finding, alleged non compliance or a requirement to make corrective changes.

Buyers should examine the background, response and current status of significant regulatory correspondence. Ignoring these matters during due diligence can result in the buyer inheriting a problem after completion.

Pharmaceutical Regulatory Liabilities

Pharmaceutical acquisitions require particularly careful regulatory review. The Drugs and Cosmetics Act, 1940 and related rules form an important part of India's framework for regulating drugs and certain related activities. The Central Drugs Standard Control Organisation also administers regulatory functions concerning drugs and medical devices at the central level. 

A buyer may therefore examine manufacturing permissions, product registrations, quality systems, inspections, recalls and regulatory correspondence. Product related issues can have long term consequences. A problem involving manufacturing quality or product compliance may affect inventory, distribution and future sales.

Where the transaction involves significant pharmaceutical operations, pharmaceutical attorneys can assist with examining sector specific regulatory obligations and potential exposure.

Medical Device Compliance

Medical device businesses can face their own regulatory requirements. The regulatory position may depend on the nature and classification of the device, its intended use and the activities conducted by the target.

Due diligence may cover registrations, manufacturing arrangements, import permissions, quality systems and regulatory communications. A buyer should also examine whether products currently sold by the target remain compliant with applicable requirements. A regulatory issue affecting a key product can have a direct impact on the commercial value of the transaction.

Clinical Establishment Regulations

Healthcare acquisitions involving hospitals and clinical facilities require review of applicable establishment and operating requirements. The Clinical Establishments (Registration and Regulation) Act, 2010 provides a statutory framework for registration and regulation of certain clinical establishments, although its application depends on the relevant jurisdiction and circumstances. 

A buyer may need to examine registration records, applicable standards and inspection history. Local regulatory requirements may also apply depending on the location and nature of the facility. The objective is to establish whether the target can continue operating under the proposed ownership structure.

Professional Compliance Matters

Healthcare operations depend on qualified professionals. Doctors, nurses, pharmacists, technicians and other healthcare professionals may be subject to professional registration and conduct requirements. A buyer should therefore examine whether key professionals have appropriate qualifications and registrations.

The review may also consider disciplinary proceedings, professional complaints and contractual arrangements. This is particularly important where the target's revenue depends heavily on a small number of specialist professionals.

Patient Data Can Create Regulatory Exposure

Healthcare businesses handle highly sensitive personal information. Patient records can contain medical histories, diagnostic results and other confidential information. A buyer should examine how patient information is collected, stored, accessed and transferred.

The Digital Personal Data Protection Act, 2023 forms part of India's developing framework for personal data processing, with the government also notifying the Digital Personal Data Protection Rules, 2025 and setting out their commencement framework.

Data security incidents, inadequate controls or poor documentation can create regulatory and litigation exposure. A buyer should therefore include data governance within healthcare due diligence rather than treating it as a separate technology issue.

Regulatory Investigations Can Survive Completion

An acquisition does not necessarily eliminate liabilities arising from the target's historical conduct. Depending on the transaction structure and applicable law, regulatory proceedings or obligations may continue after completion. This makes historical compliance particularly important.

Buyers should identify ongoing investigations, notices, inspections and unresolved corrective actions. The transaction documents can then address identified risks through appropriate representations, warranties, indemnities or conditions to completion.

Environmental and Waste Management Obligations

Healthcare facilities can generate biomedical waste and other regulated materials. Hospitals, laboratories and pharmaceutical businesses may therefore have obligations concerning storage, treatment, transportation and disposal.

Non compliance can result in regulatory action and remediation costs. Due diligence should examine relevant approvals, waste management arrangements and any history of notices or violations. These issues can be particularly important where the target operates large facilities.

Advertising and Product Claims

Healthcare and pharmaceutical businesses also need to consider how products and services are marketed. Claims about medicines, treatments, medical devices or healthcare services may be subject to applicable advertising and consumer protection requirements.

A buyer should review marketing materials and significant claims where regulatory exposure may exist. Historical marketing practices can create continuing risks if complaints or regulatory proceedings arise after completion.

Regulatory Liabilities Can Affect Valuation

Regulatory liabilities can influence transaction negotiations. A buyer may need to estimate the potential cost of resolving a regulatory issue. This can include penalties, remediation, product recalls, legal expenses and operational disruption.

The buyer may respond through a lower valuation, specific contractual protection or a requirement for the seller to resolve the matter before completion. The appropriate response depends on the seriousness and certainty of the liability. Not every regulatory issue will justify a change in transaction value. However, material uncertainty can affect the parties' assessment of risk.

Representations and Warranties Become Important

Transaction agreements commonly contain representations and warranties concerning compliance. The buyer may seek assurances about licences, regulatory proceedings, product compliance and adherence to applicable laws. These provisions should be drafted carefully.

Broad statements may not adequately address specific healthcare risks. The parties may need detailed warranties covering particular regulatory areas. Disclosure schedules can also identify known exceptions. This process helps allocate regulatory risk between the buyer and seller.

Indemnities Can Address Specific Risks

Some regulatory liabilities may be sufficiently specific to justify an indemnity. For example, the parties may identify an existing investigation, product issue or regulatory claim before completion.

An indemnity can establish how certain losses will be handled if the identified event results in financial exposure. The scope, duration and limitations of the indemnity are important. Buyers should also consider whether the seller will have sufficient financial resources to meet its obligations after completion.

Regulatory Change Can Create Future Risk

Healthcare regulation continues to evolve. A business which is compliant at the time of signing may face new requirements later. Buyers should therefore consider whether the target has systems for monitoring regulatory developments.

This is especially important in technology driven healthcare businesses, pharmaceuticals, medical devices and data intensive operations. A weak compliance function can create future exposure even where no current violation exists.

Post Acquisition Compliance Matters

Regulatory diligence should continue after completion. The buyer may need to integrate compliance policies, reporting systems and internal controls. Licences and registrations should be monitored. Regulatory correspondence should be tracked. Employees should understand any new compliance requirements. A transaction can also create organisational changes. These should not result in important regulatory responsibilities being overlooked.

Why Specialist Legal Review Matters

Healthcare regulation can involve several areas of law at the same time. A transaction may involve corporate law, healthcare regulation, pharmaceuticals, data protection, competition law, employment law and litigation.

A general corporate review may therefore not identify every sector specific issue. Specialist legal analysis can help determine whether a regulatory issue is material, whether it can be remedied and how it should be addressed in the transaction documents.

Regulatory Disputes Can Continue After an Acquisition

A regulatory issue may eventually develop into a formal dispute. This can happen where an authority challenges a licence, product approval, compliance position or other regulatory matter. The buyer may also discover a liability after completion and seek contractual remedies against the seller.

Where such issues arise, litigation lawyers for regulatory disputes may need to examine the regulatory record, transaction documents and evidence surrounding the alleged non compliance. The distinction between pre acquisition liability and post acquisition conduct can become particularly important.

Conclusion

Regulatory liabilities matter during healthcare acquisitions because they can affect the target's ability to operate, its financial position and the value of the transaction. Licences, professional registrations, product approvals, patient data, clinical standards, pharmaceutical compliance, medical devices and regulatory investigations all require careful examination. A regulatory problem does not automatically make an acquisition unsuitable. The important issue is understanding the nature, extent and potential consequences of the liability.

Thorough due diligence can help buyers identify these issues before completion. Transaction documents can then allocate identified risks through warranties, disclosures, indemnities or other appropriate protections.

For healthcare businesses, regulatory compliance should therefore be viewed as part of the underlying value of the company. A business with strong compliance systems and clear regulatory records can provide greater clarity during an acquisition, while unresolved regulatory exposure can create uncertainty long after the transaction has closed.